SignalXSignalX

NRIX Nurix Therapeutics, Inc.

8-K Current Report
Filed: March 6, 2026
Health Care
Pharmaceutical Preparations
Nurix Therapeutics, Inc. Overview

Nurix Therapeutics, Inc. (NRIX) 8-K current report filed with SEC EDGAR on March 6, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

  • Item 8.01: Other Events

AI Filing Analysis
8-K

Item 8.01 · Other Events

  • • ATM offering program expanded via Amendment No. 3 (March 6, 2026) with Piper Sandler as sales agent
  • • Total program size set at $413.65M, inclusive of shares already sold under prior amendments — net new capacity is less than this figure
+2 more insights

Get deeper insights on Nurix Therapeutics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.